Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail

v3.4.0.3
Condensed Consolidated Financial Statements Detail
3 Months Ended
Mar. 31, 2016
Condensed Consolidated Financial Statements Detail [Abstract]  
Condensed Consolidated Financial Statements Detail

3. Condensed Consolidated Financial Statements Detail

Cash and Cash Equivalents

As of March 31, 2016, cash and cash equivalents consisted of demand deposits of $3.0 million and money market funds of $43.1 million with maturities of less than 90 days at the date of purchase. As of December 31, 2015, cash and cash equivalents consisted of demand deposits of $23.2 million and money market funds of $42.6 million with maturities of less than 90 days at the date of purchase.

Marketable Securities

At March 31, 2016 and December 31, 2015, marketable securities consisted of an investment in the common stock of a public entity of $0.5 million. The Company had an unrealized loss of $42,000 associated with its marketable securities as of March 31, 2016. At each reporting date, the Company performs an evaluation of its equity securities to determine if unrealized losses are other-than-temporary. In performing this assessment, the Company determines whether it expects the security to recover in the near term and considers its ability and intent to hold the security until anticipated recovery. This determination considers the duration and severity of the impairment and the financial condition of the investment as well as the Company’s ability to hold the investment until a recovery of fair value. As of March 31, 2016, the Company determined that the unrealized loss for its marketable securities is not an other-than-temporary impairment.

Accrued and Other Liabilities  

Accrued and other liabilities consisted of the following (in thousands):

 

 

 

March 31,

2016

 

 

December 31,

2015

 

Accrued payroll and other benefits

 

$

1,573

 

 

$

2,156

 

Deferred rent

 

 

724

 

 

 

608

 

Accrued clinical trial costs

 

 

517

 

 

 

406

 

Accrued legal and accounting fees

 

 

511

 

 

 

517

 

Accrued incentive compensation

 

 

243

 

 

 

2,609

 

Accrued restructuring costs

 

 

138

 

 

 

459

 

Other

 

 

681

 

 

 

270

 

Total

 

$

4,387

 

 

$

7,025

 

 

Net Loss Per Share of Common Stock

Potentially dilutive securities are excluded from the calculation of diluted net loss per share of common stock if their inclusion is anti-dilutive.

 

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2016

 

 

2015

 

Common stock options and RSUs

 

 

10,704

 

 

 

8,756

 

Warrants for common stock

 

 

18,230

 

 

 

20,690

 

Total

 

 

28,934

 

 

 

29,446